全文获取类型
收费全文 | 50192篇 |
免费 | 5481篇 |
国内免费 | 1490篇 |
专业分类
耳鼻咽喉 | 519篇 |
儿科学 | 1045篇 |
妇产科学 | 225篇 |
基础医学 | 3977篇 |
口腔科学 | 1023篇 |
临床医学 | 7210篇 |
内科学 | 13217篇 |
皮肤病学 | 808篇 |
神经病学 | 1848篇 |
特种医学 | 842篇 |
外国民族医学 | 1篇 |
外科学 | 4498篇 |
综合类 | 8242篇 |
现状与发展 | 11篇 |
一般理论 | 3篇 |
预防医学 | 2839篇 |
眼科学 | 413篇 |
药学 | 4386篇 |
39篇 | |
中国医学 | 4382篇 |
肿瘤学 | 1635篇 |
出版年
2024年 | 78篇 |
2023年 | 1089篇 |
2022年 | 1122篇 |
2021年 | 2312篇 |
2020年 | 2357篇 |
2019年 | 2211篇 |
2018年 | 2039篇 |
2017年 | 2236篇 |
2016年 | 2415篇 |
2015年 | 2426篇 |
2014年 | 3625篇 |
2013年 | 4142篇 |
2012年 | 3094篇 |
2011年 | 3419篇 |
2010年 | 2624篇 |
2009年 | 2388篇 |
2008年 | 2229篇 |
2007年 | 2341篇 |
2006年 | 2032篇 |
2005年 | 1773篇 |
2004年 | 1412篇 |
2003年 | 1218篇 |
2002年 | 1106篇 |
2001年 | 961篇 |
2000年 | 810篇 |
1999年 | 615篇 |
1998年 | 477篇 |
1997年 | 475篇 |
1996年 | 434篇 |
1995年 | 461篇 |
1994年 | 413篇 |
1993年 | 350篇 |
1992年 | 302篇 |
1991年 | 248篇 |
1990年 | 219篇 |
1989年 | 203篇 |
1988年 | 158篇 |
1987年 | 144篇 |
1986年 | 138篇 |
1985年 | 209篇 |
1984年 | 151篇 |
1983年 | 108篇 |
1982年 | 126篇 |
1981年 | 137篇 |
1980年 | 80篇 |
1979年 | 63篇 |
1978年 | 57篇 |
1977年 | 47篇 |
1976年 | 37篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
21.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
22.
23.
目的 探讨不同时期慢性阻塞性肺疾病(COPD)患者血清诱饵受体3(DcR3)、凋亡抑制蛋白(Survivin)表达水平及临床意义。方法 选取2018年9月—2019年12月本院收治的92名COPD患者为研究对象,其中稳定型COPD 50例,急性加重期COPD 42例;同期本院健康体检者88例为对照组。测定各组研究对象血清DcR3、Survivin水平及肺功能指标。 与对照组[DcR3(106.54±48.35)pg/mL,Survivin(98.85±26.59)pg/mL]比较,稳定期组和急性加重期组血清DcR3[(395.23±123.85)pg/mL,(1 248.81±213.59)pg/mL]、Survivin [(267.54±84.69)pg/mL,(1 233.95±307.26)pg/mL]水平升高;与稳定期组比较,急性加重期组血清DcR3、Survivin水平升高。与对照组比较,稳定期组和急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001);与稳定期组比较,急性加重期组FEV1%、FEV1 /FVC、DLCO%水平降低(P<0.001)。随着低氧血症严重程度的增加,COPD患者血清DcR3、Survivin水平逐渐增加(P<0.001)。多因素logistics回归分析显示,高水平DcR3、Survivin、IL-12、hs-CRP为COPD病情的危险因素(P<0.001)。DcR3、Survivin与FEV、FEV1 /FVC呈负相关,与IL-12、TNF-α、hs-CRP呈正相关(P<0.001)。 COPD稳定期、急性加重期患者血清DcR3、Survivin表达水平升高,且DcR3、Survivin与COPD病情严重程度呈正相关。 相似文献
25.
26.
27.
Peter H. Egbers Anna-Liisa Sutt Jenny E. Petersson Liza Bergström Eva Sundman 《Acta anaesthesiologica Scandinavica》2023,67(10):1403-1413
Background
Weaning from mechanical ventilation and tracheostomy after prolonged intensive care consume enormous resources with optimal management not currently well described. Restoration of respiratory flow via the upper airway is essential and early cuff-deflation using a one-way valve (OWV) is recommended. However, extended OWV use may cause dry airways and thickened secretions which challenge the weaning process. High-flow therapy via the tracheostomy tube (HFT-T) humidifies inspired air and may be connected via an in-line OWV (HFT-T-OWV) alleviating these problems. We aim to provide clinical and experimental data on the safety of HFT-T-OWV along with a practical guide to facilitate clinical use during weaning from mechanical ventilation and tracheostomy.Methods
Data on adverse events of HFT-T-OWV were retrieved from a quality register for patients treated at an intensive care rehabilitation center between 2019 and 2022. Benchtop experiments were performed to measure maximum pressures and pressure support generated by HFT-T-OWV at 25–60 L/min flow using two different HFT-T adapters (interfaces). In simulated airway obstruction using a standard OWV (not in-line) maximum pressures were measured with oxygen delivered via the side port at 1–3 L/min.Results
Of 128 tracheostomized patients who underwent weaning attempts, 124 were treated with HFT-T-OWV. The therapy was well tolerated, and no adverse events related to the practice were detected. The main reason for not using HFT-T-OWV was partial upper airway obstruction using a OWV. Benchtop experiments demonstrated HFT-T-OWV maximum pressures <4 cmH2O and pressure support 0–0.6 cmH2O. In contrast, 1–3 L/min supplemental oxygen via a standard OWV caused pressures between 84 and 148 cmH2O during simulated airway obstruction.Conclusions
Current study clinical data and benchtop experiments indicate that HFT-T-OWV was well tolerated and appeared safe. Pressure support was low, but humidification may enable extended use of a OWV without dry airway mucosa and thickened secretions. Results suggest the treatment could offer advantages to standard OWV use, with or without supplementary oxygen, as well as to HFT-T without a OWV, for weaning from mechanical ventilation and tracheostomy. However, for definitive treatment recommendations, randomized clinical trials are needed. 相似文献28.
29.
目的对医院制剂通鼻消涕颗粒对慢性鼻窦炎鼻黏膜功能是否有调控作用进行临床研究。方法 收集慢性鼻窦炎不伴鼻息肉患者,采用单盲方法随机将患者分为治疗组(通鼻消涕颗粒组)和对照组(克拉霉素片组)。分别给予口服通鼻消涕颗粒和克拉霉素片治疗4周,并对治疗前、治疗2周后、治疗4周后的患者进行糖精试验、鼻部症状VAS评分与鼻内镜Lund Kennedy评分。并采用t检验统计分析。比较服药前、服药后的评分变化。结果 VAS评分提示:治疗组中,治疗2周后、治疗4周后与治疗前相比差异均有统计学意义(P<0.05),对照组在治疗后的各个阶段与治疗前相比均无明显差异(P>0.05)。Lund Kennedy评分提示:治疗组在治疗2周后与治疗前无明显差异,但在治疗4周后有明显改善(P<0.05),对照组则在治疗后各个阶段无明显变化(P>0.05)。糖精试验提示2组在治疗后2周患者糖精清除时间差异无统计学意义(P>0.05),但治疗组在治疗4周后患者糖精清除时间低于对照组(P<0.05)。结论 通鼻消涕颗粒对慢性鼻窦炎的鼻黏膜形态与传输功能有明显改善作用,可以促进鼻黏膜纤毛功能的恢复,并优于克拉霉素片组,且无毒副作用,值得临床上推广应用。 相似文献
30.
目的利用多体素氢质子磁共振波谱成像(hydrogen proton magnetic resonance spectroscopy,1H-MRS)探讨慢性高原病(chronic mountain sickness,CMS)长期缺氧状态下脑部代谢物的特点,并比较各代谢物与血液指标之间的相关性。材料与方法前瞻性纳入青海大学附属医院经临床确诊为CMS的17例男性患者作为实验组,年龄(53.29±9.03)岁,居住海拔(3989.12±937.45)m,血红蛋白(hemoglobin,HGB)(224.35±11.81)g/mL,并招募与实验组年龄及居住海拔相匹配的18名健康男性志愿者作为对照组,年龄(48.61±8.76)岁,居住海拔(3674.94±634.27)m,HGB(156.67±9.46)g/mL。采用Siemens Prisma 3.0 T MR扫描仪20通道头颅线圈对所有受试者行常规头颅MRI及多体素;H-MRS检查,通过Syngo.via后处理软件获得;H-MRS图,ROI选取双侧额叶及海马区,并获得相应脑区N-乙酰天门冬氨酸/肌酸(NAA/Cr)、胆碱/肌酸CHo/Cr、乙酰天门冬氨酸/胆碱(NAA/CHo)、乳酸/肌酸(Lac/Cr)的比值。结合独立样本t检验及非参数曼-惠特尼U检验以比较两组间代谢物相对浓度差异,然后将CMS组双侧额叶及海马区各代谢物比值与血液生化指标作相关性分析。结果(1)两组受试者年龄、长期居住海拔差异均无统计学意义(P>0.05),而与对照组相比,CMS组HGB、红细胞计数(red blood cell count,RBC)、血细胞比容(hematocrit,HCT)增高,血小板(blood platelet,简称PLT)减低,差异均有统计学意义(P<0.01);(2)与对照组相比,CMS组双侧额叶及海马区NAA/Cr及NAA/CHo均减低(P<0.05),Lac/Cr增高(P<0.05),差异均具有统计学意义;(3)与对照组相比,CMS组双侧额叶及双侧海马区CHo/Cr均增高(P>0.05),差异无统计学意义;(4)CMS组右侧额叶及左侧海马CHo/Cr与RBC明显正相关,左侧额叶CHo/Cr与HCT低度正相关,右侧额叶及左侧海马Lac/Cr与HCT低度正相关。结论CMS长期缺氧状态下脑组织局部代谢物改变,神经元受损,无氧代谢增加,且这些代谢物的改变与血液指标呈一定的相关性,可为临床后续进一步预防或干预CMS患者脑损害提供影像学证据及监测指标。 相似文献